OXFORD COVID-19 Vaccine 70% Effective.

India likely to get it's Oxford COVID vaccine, 70% effective. 

Adar Poonawala, CEO of  Serum Institute of India(SII) says company will be applying for the emergency licensure very soon and expects to get it in a month, but the final approval depends on the decision of Directorate General of Commercial Intelligence(DGCI).

The Serum  Institute of India, Pune is now all set to seek emergency regulatory approval by the Government of India Authorities and go-ahead by year-end for Oxford COVID-19 Vaccine AstraZeneca. The Vaccine trials have shown 70% effectiveness in preventing people from getting infected from COVID-19. Positive data of AstraZeneca trial has raised hope for the faster rollout of vaccine in India. The first batch of AstraZeneca vaccine will be made available for healthcare workers and vulnerable and elderly people aged above 65.

SII CEO also informed, that the company has stockpiled around 4 crore doses  and will reached around 10 crore doses by January 2021.

The clinical trials of AZD1222,  globally evaluated participants over 18 years, has shown one dosing regimen with a vaccine efficacy of 90% when half a dose which is followed by a full does at a gap of one month was given. The other regimen has shown 62% efficacy when the two full doses vaccine was given, with a gap of at least 1 month. The combined analysis from both the dosing regimens of vaccine has result in an average efficacy of 70%. The safety of AstraZeneca was conformed by the CEO of SII, that it will be highly effective against COVID-19 and will also have an immediate effect on public health emergency. 

                                      


The vaccine can be stored in at fridge temperature (2-8 degree Celsius)  rather than a freezer. This will make is easier to delivery the vaccine across the world and administer it in existing healthcare setting. India's COVID vaccine will be available at almost half the rate, as it will be making bulk purchases, India may get the vaccine at 50 percent of its actual MRP, which is Rs 500-600 for the two-shot vaccine. The company will be seeking an emergency use listing from WHO for a pathway to vaccine availability in low-income countries.

                                                                     

IF YOU LIKE IT, DO SHARE

THANK YOU!!

 

Popular posts from this blog

5 Simple Marketing Ideas Needed For Small Business Owners.

India's first 'MOSS GARGEN' in Nainital District.

Responsibilities & Duties of a Digital Marketer ( for beginners).